Nanocarry
Ayelet Zafran is the Vice President of Research and Development at Nanocarry Therapeutics, a position held since December 2022, and previously served as a Senior Scientist. Prior experience includes roles as a Bioprocess Scientist and Scientist at Teva Pharmaceuticals from January 2020 to December 2022, as well as a Senior Scientist at Beta-o2 for a brief period in 2019. Ayelet Zafran also worked as a Teaching Assistant at Tel Aviv University from 2010 to 2017. Academic credentials include a PhD in Cancer Biophysics, an MSc in Neuroscience, and a BSc in Life Science, all from Tel Aviv University, with studies completed between 2005 and 2018.
This person is not in any teams
This person is not in any offices
Nanocarry
Nanocarry is developing a new class of therapeutics based on bioengineered nanoparticles with novel capabilities to treat oncology indications and brain diseases. Using a proprietary “Plug and Play” approach, Nanocarry’s AxS platform can be easily modified to deliver a wide array of biologics, safely and effectively, to the brain and beyond. Nanocarry’s first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer.